Alkermes Gets Drug Approval

Xconomy Boston — 

Waltham, MA-based biotech firm Alkermes (NASDAQ:ALKS) said today that the FDA has approved its extended-release formulation of naltrexone (Vivitrol) for preventing the relapse of opioid drug dependence. The firm’s drug, which is injected once per month, was initially approved for alcohol dependence in 2006. The company will discuss the new approval of the drug during a conference call scheduled for 8 am ET on Wednesday.